Drug Trial Radar · NCT02047734
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Feb 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,320
Actual
Start
Dec 3, 2013
Primary completion
Mar 27, 2017
Study completion Apr 13, 2017
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 28, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).
Conditions
- Relapsing Multiple Sclerosis
Interventions
OzanimodDrug
Oral capsule, daily for 24 months
Ozanimod placeboDrug
Oral capsule, daily for 24 months
Interferon beta-1aDrug
Intramuscular injection, 30 µg, weekly for 24 months
Interferon beta-1a placeboDrug
Intramuscular injection, weekly for 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjusted Annualized Relapse Rate (ARR) at the End of Month 24Time frame: At the end of month 24
Locations
299 sites in 21 countries. Site status is shown where the registry gives one.
Receptos Study Site 115
Phoenix, Arizona
Xenoscience
Phoenix, Arizona
Receptos Study Site 118
Phoenix, Arizona
Saint Josephs Hosptial and Medical Center
Phoenix, Arizona
Territory Neurology and Research Institute
Tucson, Arizona
Receptos Study Site 119
Tucson, Arizona
Alta Bates Summit Medical Center
Berkeley, California
Receptos Study Site 110
Berkeley, California
Receptos Study Site 122
Long Beach, California
Receptos Study Site 112
Sacramento, California
University of California Davis Medical Center
Sacramento, California
Multiple Sclerosis Center at UCSF
San Francisco, California
Receptos Study Site 120
San Francisco, California
Denver Neurological Research LLC
Denver, Colorado
Receptos Study Site 127
Denver, Colorado
Neurology Associates PA
Maitland, Florida
Receptos Study Site 114
Maitland, Florida
Receptos Study Site 124
Pompano Beach, Florida
Neurostudies Inc
Port Charlotte, Florida
Receptos Study Site 123
Port Charlotte, Florida
Infinity Clinical Research LLC
Sunrise, Florida
West Georgia Sleep Disorder Center and Neurology Associates
Douglasville, Georgia
Consultants In Neurology
Northbrook, Illinois
Receptos Study Site 113
Northbrook, Illinois
Receptos Study Site 121
St Louis, Missouri
Washington University
St Louis, Missouri
Receptos Study Site 101
Charlotte, North Carolina
The Neurological Institute PA
Charlotte, North Carolina
Neurology and Neuroscience Associates Inc.
Akron, Ohio
Receptos Study Site 107
Akron, Ohio
Receptos Study Site 104
Cleveland, Ohio
Receptos Study Site 109
Philadelphia, Pennsylvania
Receptos Study Site 102
Seattle, Washington
The Polyclinic
Seattle, Washington
Receptos Study Site 125
Tacoma, Washington
Grodno Clinical Regional Hospital
Grodno, Belarus
Receptos Study Site 907
Grodno, Belarus
Gomel Regional Clinical Hospital
Homyel, Belarus
Receptos Study Site 904
Homyel, Belarus
Minsk Municipal Clinical Hospital 5
Minsk, Belarus
Showing 40 of 299 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.